Bevacizumab in the treatment of pterygium: A meta-analysis

Cornea

Volumn 33, Issue 2, 2014, Pages 154-160

  Hu, Qiongwen ^a   Qiao, Yanbing ^b   Nie, Xin ^b   Cheng, Xiaocheng ^c   Ma, Yongping ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Clinical Laboratory Center of Chongqing   (China)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Meta analysis; Pterygium

Indexed keywords

BEVACIZUMAB; EYE DROPS; PLACEBO; VASCULOTROPIN;

ARTICLE; CONJUNCTIVA DISEASE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REGRESSION ANALYSIS; RISK ASSESSMENT; SUBCONJUNCTIVAL HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; HUMANS; INTRAOPERATIVE COMPLICATIONS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; PTERYGIUM; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892975978     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000037     Document Type: Article

References (32)

1. Manning CA, Kloess PM, Diaz MD, et al. Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. Ophthalmology. 1997;104:844-848.
2. Detorakis ET, Spandidos DA. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives (review). Int J Mol Med. 2009;23:439-447.
3. Bahar I, Kaiserman I, Weisbrod M, et al. Extensive versus limited pterygium excision with conjunctival autograft: Outcomes and recurrence rates. Curr Eye Res. 2008;33:435-440.
4. Murube J. Pterygium: Its treatment with beta therapy. Ocul Surf. 2009;7: 3-9.
5. Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium: A report by the American Academy of Ophthalmology. Ophthalmology. 2013;120:201-208.
6. Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf. 2007;6:27-32.
7. Kareem AA, Farhood QK, Alhammami HA. The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium. Clin Ophthalmol. 2012;6:1849-1854.
8. Bekibele CO, Ashaye A, Olusanya B, et al. 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence. Int Ophthalmol. 2012;32:3-8.
9. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007; 69:925-927.
10. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477.
11. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond). 2007;21:1095-1101.
12. Di Girolamo N, Coroneo MT, Wakefield D. Active matrilysin (MMP-7) in human pterygia: Potential role in angiogenesis. Invest Ophthalmol Vis Sci. 2001;42:1963-1968.
13. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
14. Bahar I, Yeung SN, Sella R, et al. Anterior segment uses of bevacizumab. Curr Opin Ophthalmol. 2012;23:303-316.
15. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group, Cochrane StatisticalMethods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996;17:1-12.
17. Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104:974-985.
18. Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43:134-138.
19. Shenasi A, Mousavi F, Shoa-Ahari S, et al. Subconjunctival bevacizumab immediately after excision of primary pterygium: The first clinical trial. Cornea. 2011;30:1219-1222.
20. Ozgurhan EB, Agca A, Kara N, et al. Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea. 2013;32:835-838.
21. Nava-Castañeda A, Olvera-Morales O, Ramos-Castellon C, et al. Randomized controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: One year follow-up. Clin Experiment Ophthalmol. 2013; doi:10.1111/ceo.12140.
22. Lekhanont K, Patarakittam T, Thongphiew P, et al. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: A pilot study. Cornea. 2012;31:155-161.
23. Fallah MR, Khosravi K, Hashemian MN, et al. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010;35:17-22.
24. Shahin MM, Elbendary AM, Elwan MM. Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: A preliminary report. Ophthalmic Surg Lasers Imaging. 2012;43:459-466.
25. Banifatemi M, Razeghinejad MR, Hosseini H, et al. Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther. 2011;27:17-21.
26. Enkvetchakul O, Thanathanee O, Rangsin R, et al. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results. Cornea. 2011;30:1213-1218.
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
28. Hirst LW. The treatment of pterygium. Surv Ophthalmol. 2003;48: 145-180.
29. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
30. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
31. Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Clin Ophthalmol. 2011;5:841-845.
32. Pan HW, Zhong JX, Jing CX. Comparison of fibrin glue versus suture for conjunctival autografting in pterygium surgery: A meta-Analysis. Ophthalmology. 2011;118:1049-1054.